Literature DB >> 19135746

The first report of late stent thrombosis leading to acute myocardial infarction in patient receiving the new endothelial progenitor cell capture stent.

Marco L Rossi1, Dennis Zavalloni, Gabriele L Gasparini, Ruggiero Mango, Guido Belli, Patrizia Presbitero.   

Abstract

The endothelial progenitor cell (EPC) capture stent is a stainless steel coronary stent covered with antibodies specific to EPC's surface antigens, designed to promote the faster formation of a functional endothelial lining. This may prevent both stent thrombosis and restenosis as well as reduce the need of prolonged double antiplatelet therapy. Here we report a case of late (156 days after implantation) EPC capture stent thrombosis and re-stenosis of a second EPC capture stent occurring both in the same patient after withdrawal of clopidogrel. Intravascular ultrasound performed during his acute admission showed undersizing of the stent with thrombosis. The present case raises the question about the safety of the EPC capture stent and the need to prolong at least for 6 months double antiplatelet therapy also in patients receiving this new stent. Copyright (c) 2008 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19135746     DOI: 10.1016/j.ijcard.2008.11.134

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  8 in total

1.  Anti-platelet and tissue engineering approaches to biomaterial blood compatibilization: how well have these been translated into the clinic?

Authors:  Scott Alexander Irvine; Xia Yun; Subbu Venkatraman
Journal:  Drug Deliv Transl Res       Date:  2012-10       Impact factor: 4.617

2.  Enhanced human endothelial progenitor cell adhesion and differentiation by a bioinspired multifunctional nanomatrix.

Authors:  Adinarayana Andukuri; Young-Doug Sohn; Chidinma P Anakwenze; Dong-Jin Lim; Brigitta C Brott; Young-Sup Yoon; Ho-Wook Jun
Journal:  Tissue Eng Part C Methods       Date:  2012-12-19       Impact factor: 3.056

3.  First in vitro and in vivo results of an anti-human CD133-antibody coated coronary stent in the porcine model.

Authors:  Alexander Sedaghat; Jan-Malte Sinning; Kathrin Paul; Gregor Kirfel; Georg Nickenig; Nikos Werner
Journal:  Clin Res Cardiol       Date:  2013-02-10       Impact factor: 5.460

4.  A selective microRNA-based strategy inhibits restenosis while preserving endothelial function.

Authors:  Gaetano Santulli; Anetta Wronska; Kunihiro Uryu; Thomas G Diacovo; Melanie Gao; Steven O Marx; Jan Kitajewski; Jamie M Chilton; Kemal Marc Akat; Thomas Tuschl; Andrew R Marks; Hana Totary-Jain
Journal:  J Clin Invest       Date:  2014-08-18       Impact factor: 14.808

Review 5.  Microfabrication and nanotechnology in stent design.

Authors:  Adam W Martinez; Elliot L Chaikof
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2011-01-31

6.  Constructing bio-layer of heparin and type IV collagen on titanium surface for improving its endothelialization and blood compatibility.

Authors:  Kun Zhang; Jun-ying Chen; Wei Qin; Jing-an Li; Fang-xia Guan; Nan Huang
Journal:  J Mater Sci Mater Med       Date:  2016-03-02       Impact factor: 3.896

7.  Combination coating of chitosan and anti-CD34 antibody applied on sirolimus-eluting stents can promote endothelialization while reducing neointimal formation.

Authors:  Feng Yang; Shi-Chao Feng; Xiang-Jun Pang; Wei-Xiao Li; Yong-Hua Bi; Qian Zhao; Shi-Xuan Zhang; Yang Wang; Bo Feng
Journal:  BMC Cardiovasc Disord       Date:  2012-10-26       Impact factor: 2.298

8.  In situ re-endothelialization via multifunctional nanoscaffolds.

Authors:  Lee-Chun Su; Hao Xu; Richard T Tran; Yi-Ting Tsai; Liping Tang; Subhash Banerjee; Jian Yang; Kytai T Nguyen
Journal:  ACS Nano       Date:  2014-09-15       Impact factor: 15.881

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.